Vyne Therapeutics has dosed the first participant in a randomised Phase Ib clinical trial of VYN202, an oral treatment for moderate-to-severe plaque psoriasis. The double-blind, placebo-controlled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback